Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

NEXT STORY
2020 Outlook on the Worldwide COVID-19 Market – Events That Pushed Share Prices Up
PREV STORY
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chembio Diagnostics Names John Potthoff, Ph.D. to its Board of Directors

MEDFORD, N.Y., May 16, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in ...

author_avatar
NASDAQ Market News

BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia

author_avatar
NASDAQ Market News

Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021

author_avatar
NASDAQ Market News